Netherlands, April 6, 2007 – Preliminary results from recent human studies conducted at RMIT University in Australia show significant effects of flaxseed lignans intake on biomarkers of breast cancer risk in postmenopausal women. The studies reveal flaxseed lignans significantly influence endogenous sex hormone production, metabolism and biological activity and may exert significant antiestrogenic effects which are associated with the decreased risk of breast health. These findings add to previous scientific evidence showing the beneficial effects of flaxseed lignans on breast health.
Breast cancer is one of the most common cancers in women. According to the American Cancer Society, the chance of a woman having invasive breast cancer sometime in her life is 1 in 7. As such, having a natural alternative to other preventive measures such as diet and exercise becomes increasingly important.
This study is crucial for those who are at risk of breast cancer because it affirms that flaxseed lignans, when consumed, are converted to enterolactone and enterodiol, that work against the estrogens in our bodies that promote the growth of breast cancers. Results from the first randomized double-blind placebo-controlled trial showed that flaxseed lignans were metabolized to enterolactone and enterodiol in a dose response manner and were therefore available to exert antiestrogenic effects and influence endogenous sex hormone production, metabolism and biological activity. Results from the second double-blind placebo-controlled trial support the results from the first trial.
A growing body of research suggests that flaxseed lignans may be protective against breast cancer. A study published in 20061 reported that women who had a higher lignan intake decreased their risk of breast cancer by 58 percent. Another study conducted in 19992 showed that flaxseed had protective effects against breast cancer in postmenopausal women.
Flaxseed and specifically its lignans are reported to have beneficial effects on acne, hair loss, menopause, breast health, postmenopausal symptoms, cardiovascular health and prostate health in men. These beneficial effects have been repeatedly validated by data from in vitro model systems, animal studies, and intervention trials in humans.
Frutarom’s LinumLife is a unique flax ingredient rich in lignans. Lignans are intensively researched for their phytoestrogenic effects. LinumLife provides lignans in a 10 to 30 times higher concentration than any other flax ingredient. Lignans are phytoestrogens, which are scientifically related to many beneficial effects on health such as:pProstate health, hair loss, acne, antioxidant, menopause, osteoporosis, cholesterol, and blood sugar. For more information, please visit www.linumlife.com.
Frutarom was established in 1933. With a current market capitalization of over US$ 480 million, it is a rapidly growing multinational flavors and fine ingredients company, employing about 1,200 people. It develops, manufactures and markets an extensive variety of high quality flavors and natural fine ingredients for customers in various industries: the food-, beverage and functional food industries as well as the flavor-, fragrance- pharmaceutical, dietary supplement and cosmetic industries. Frutarom markets and sells over 15,000 products to more than 5,000 customers in over 120 countries and keeps manufacturing facilities in Europe, North America, Israel and Asia. The company operates worldwide through local agents and distributors.
Frutarom operates through two divisions: The Flavors Division develops, produces and markets flavor compounds and food systems, while the Fine Ingredients Division is responsible for the whole process from development to sale of natural flavor extracts, functional food ingredients and pharma/nutraceutical extracts, as well as specialty essential oils, citrus products and aroma chemicals.
Over recent years, Frutarom has implemented a successful rapid growth strategy that combines above industry-average organic growth in its core activities together with strategic acquisitions of synergetic companies and activities. In the course of the last decade, Frutarom has acquired fourteen businesses, including the Swiss company Emil Flachsmann AG in 2003, the European food system activities of IFF in 2004, the Nesse group in January and Acatris Health in October 2006.
Frutarom Industries, Ltd. is a public company whose stock is listed on the Tel Aviv and London Stock Exchanges. For further information, visit our website: www.frutarom.com.
1 Piller, R., Chang-Claude, J., & Linseisen, J. (2006). Plasma enterolactone and genistein and the risk of premenopausal breast cancer. European Journal of Cancer Prevention, 15, 225-232.
2 Haggans, C.J. et al. (1999). Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutrition and Cancer, 33(2), 188-195.
# # #